Literature DB >> 24337622

Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients.

Fumihiko Furuya1, Hiroki Shimura, Hiroshi Yokomichi, Kazuya Takahashi, Daiichiro Akiyama, Chikako Asakawa, Ayako Okamura, Ai Motosugi, Kazutaka Haraguchi, Zentaro Yamagata, Tetsuro Kobayashi.   

Abstract

BACKGROUND: Elevated levels of neutrophil gelatinase-associated lipocalin (NGAL) have been reported in patients with cardiovascular disease (CVD), heart failure, and stroke. We assessed the relationships between serum levels of NGAL and the prevalence of CVD, and clarified the prognostic usefulness of systemic NGAL levels in hemodialysis (HD) patients.
METHODS: Eighty-eight HD patients were followed up for 1 year. Logistic regression analyses were used to investigate the relationship between de novo CVD status and NGAL levels as well as other risk factors.
RESULTS: During follow-up, CVD events occurred in 20 patients. Initial serum levels of NGAL and brain natriuretic peptide of HD patients with de novo CVD were significantly higher than those of HD patients without de novo CVD. Multivariate logistic regression analyses showed that initial serum levels of NGAL were independent risk factors for de novo CVD in HD patients. When patients were classified on the basis of NGAL quartiles, multiple logistic regression analyses demonstrated that the highest quartile of NGAL level showed an increased odds ratio for the prevalence of CVD.
CONCLUSION: These findings suggest that NGAL levels can be used to detect the prevalence of CVD in HD patients with or without diabetes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337622     DOI: 10.1007/s10157-013-0923-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  23 in total

1.  Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.

Authors:  Makoto Suzuki; Yoshiyuki Hada; Makoto Akaishi; Michiaki Hiroe; Kazutaka Aonuma; Yoshiharu Tsubakihara; Tadao Akizawa
Journal:  Int Heart J       Date:  2012       Impact factor: 1.862

2.  A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI).

Authors:  Kohji Shirai; Junji Utino; Kuniaki Otsuka; Masanobu Takata
Journal:  J Atheroscler Thromb       Date:  2006-04       Impact factor: 4.928

3.  Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Authors:  Yoshiyuki Morishita; Shiho Hanawa; Junko Chinda; Osamu Iimura; Sadao Tsunematsu; Eiji Kusano
Journal:  Hypertens Res       Date:  2010-12-02       Impact factor: 3.872

Review 4.  Natriuretic peptides and NGAL in heart failure: does a link exist?

Authors:  Alberto Palazzuoli; Matteo Beltrami; Marco Pellegrini; Ranuccio Nuti
Journal:  Clin Chim Acta       Date:  2012-07-20       Impact factor: 3.786

5.  Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90.

Authors:  Koshi Nakamura; Tomonori Okamura; Takehito Hayakawa; Takashi Kadowaki; Yoshikuni Kita; Hirofumi Ohnishi; Shigeyuki Saitoh; Kiyomi Sakata; Akira Okayama; Hirotsugu Ueshima
Journal:  Circ J       Date:  2006-08       Impact factor: 2.993

6.  Low serum testosterone increases mortality risk among male dialysis patients.

Authors:  Juan Jesús Carrero; Abdul Rashid Qureshi; Paolo Parini; Stefan Arver; Bengt Lindholm; Peter Bárány; Olof Heimbürger; Peter Stenvinkel
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

7.  Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure.

Authors:  Arne Yndestad; Linn Landrø; Thor Ueland; Christen P Dahl; Trude H Flo; Leif Erik Vinge; Terje Espevik; Stig S Frøland; Cathrine Husberg; Geir Christensen; Kenneth Dickstein; John Kjekshus; Erik Øie; Lars Gullestad; Pål Aukrust
Journal:  Eur Heart J       Date:  2009-03-26       Impact factor: 29.983

8.  Cardio-ankle vascular index to screen cardiovascular diseases in patients with end-stage renal diseases.

Authors:  Tsuneo Takenaka; Hitoshi Hoshi; Nobutaka Kato; Kazuyuki Kobayashi; Hiroshi Takane; Junko Shoda; Hiromichi Suzuki
Journal:  J Atheroscler Thromb       Date:  2008-12-06       Impact factor: 4.928

Review 9.  Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage.

Authors:  Davide Bolignano; Valentina Donato; Giuseppe Coppolino; Susanna Campo; Antoine Buemi; Antonio Lacquaniti; Michele Buemi
Journal:  Am J Kidney Dis       Date:  2008-04-02       Impact factor: 8.860

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  6 in total

Review 1.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

Review 2.  Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Authors:  Emilie Viennois; Yuan Zhao; Didier Merlin
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

3.  Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.

Authors:  Yalcin Solak; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Hilmi Umut Unal; Halil Yaman; Mahmut Gok; Hakki Cetinkaya; Abduzhappar Gaipov; Tayfun Eyileten; Sebahattin Sari; Ali Osman Yildirim; Halil Zeki Tonbul; Suleyman Turk; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-10-26       Impact factor: 2.370

Review 4.  Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability.

Authors:  Luis D'Marco; Antonio Bellasi; Paolo Raggi
Journal:  Dis Markers       Date:  2015-04-05       Impact factor: 3.434

5.  Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study-Impact for mortality.

Authors:  Rainer P Woitas; Hubert Scharnagl; Marcus E Kleber; Graciela E Delgado; Tanja B Grammer; Martin Pichler; Bernhard K Krämer; Winfried März; Tatjana Stojakovic
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

Review 6.  Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Shinichiro Niizuma; Yoshitaka Iwanaga; Takaharu Yahata; Shunichi Miyazaki
Journal:  Front Cardiovasc Med       Date:  2017-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.